All In Biotech

NDA 208743 · Radius

Tymlos

Abaloparatide · Subcutaneous · Parathyroid Hormone-Related Peptide Analog

Novel

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Apr 28, 2017

Approved uses

5

Original approval plus efficacy supplements

Registered trials

18

6 Phase 3, 1 recruiting

FAERS reports

31,042

5,492 serious, 327 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 11, 2026.

TYMLOS is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1.1 ) Treatment to increase bone density in men with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1.2 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture TYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures. 1.2 Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture TYMLOS is indicated to increase bone density in men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy.

Mechanism: Abaloparatide is a PTHrP(1-34) analog which acts as an agonist at the PTH1 receptor (PTH1R). This results in activation of the cAMP signaling pathway in target cells. Once-daily administration of abaloparatide stimulates new bone formation on trabecular and cortical bone surfaces by stimulation of osteoblastic activity. In rats and monkeys, abaloparatide had an anabolic effect on bone, demonstrated by increases in BMD and bone mineral content (BMC) that correlated with increases in bone strength at vertebral and/or nonvertebral sites [see Nonclinical Toxicology ( 13.2 )] .

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 19, 2022 Supplement 13 · Efficacy Label
  • Dec 22, 2021 Supplement 10 · Efficacy Label
  • Sep 20, 2021 Supplement 9 · Efficacy LabelLetter
  • Oct 17, 2018 Supplement 3 · Efficacy LabelLetter
  • Apr 28, 2017 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
  • TYMLOS · ABALOPARATIDE 3.12MG/1.56ML (2MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Abaloparatide" as an intervention, any sponsor and status, largest first.

All 18 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache5,459
  • nausea4,169
  • dizziness4,144
  • fatigue3,666
  • product dose omission issue2,863
  • heart rate increased2,773
  • arthralgia2,533
  • palpitations2,380
  • bone pain1,939
  • pain1,687
  • back pain1,641
  • injection site bruising1,289

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20163
2017237
20182,958
20193,006
20201,727
20212,031
20222,039
20232,756
20243,634
20256,308
20266,342

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tymlos (Abaloparatide)

2024 spending

$258M

Beneficiaries

16,530

88,564 claims

Per beneficiary

$15,586

$1,690.96 per unit

View as table
YearSpending
2020$132,756,710
2021$137,835,466
2022$156,712,784
2023$197,623,448
2024$257,643,485

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 68 on PubMed

Sponsor: Radius

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.